Stock Analiz

Immucell Corp. ICCC

Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 1987 · data as of November 13, 2026

$10.75Market cap $98M
Open the interactive analysis →

Immucell Corp. (ICCC) is a healthcare company listed in the US with a market value of about $98M. In the twelve months to September 30, 2026 it had revenue of $33M and net income of $2M, a net margin of 5.7%.

Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (1/5).

Key numbers: a P/E of 56.6, a price to free cash flow of 18.1, 5-year revenue growth of 12% a year, a 5-year average ROIC of -2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.

About Immucell

Immucell is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 1987. Revenue went from $8M in 2014 to $28M in 2025, growth of about 12.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 17% over three years (dilution for shareholders). It spends 11% of revenue on research and development.

Score: 2.0 / 5

Value1/5
Future growth3/5
Track record1/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • P/FCF below 20
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)56.6
Forward P/E—
P/FCF18.1
P/S2.9
P/B3.0
EV/EBITDA14.6
PEG—
Dividend yield0.00%
FCF yield5.5%
Shareholder yield0.0%
Intrinsic value vs. price−80%

Growth and quality

Revenue growth (1 yr)4.3%
Revenue growth (5 yrs, per year)12.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-11.8%
ROIC (5-yr avg.)-2.4%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$33M$28M$26M$17M$19M$19M$15M$14M$11M$10M$10M
Net income$2M-$1M-$2M-$6M-$2M-$78292-$1M-$1M-$2M-$168147$508448
Free cash flow$5M$1M-$107822-$7M-$6M-$2M-$3M-$1M-$2M-$17M-$4M
EPS (diluted)$0.19$-0.12$-0.26$-0.75$-0.32$-0.01$-0.14$-0.19$-0.42$-0.03$0.12
Net margin5.7%-3.8%-8.1%-33.1%-13.4%-0.4%-6.7%-9.4%-21.1%-1.6%5.3%
ROIC—3.2%-3.0%-9.0%-3.6%0.6%-3.5%-2.0%-3.7%-0.6%3.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Immucell’s P/E ratio?

About 56.6, based on the last twelve months of diluted earnings per share.

Is Immucell stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Immucell pay a dividend?

Not currently.

Is Immucell a good stock to buy?

We do not give buy or sell advice. Immucell scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.